Tailored radiation blasts brain tumors where They're most likely to return

NCT ID NCT03477513

Completed Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests a personalized approach to radiation therapy for people with glioblastoma, an aggressive brain cancer. After surgery, each participant receives a radiation plan that delivers a higher dose to the areas where the tumor is most likely to come back. The goal is to see if this tailored treatment can delay cancer progression and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Personalized radiation therapy
What this could lead to: If successful, this approach could offer a more effective way to target glioblastoma, potentially extending the time before the cancer returns.
What could go wrong: This is a small pilot study, so results may not apply to all patients. The higher radiation dose could also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Show contact details

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.